Multivariable analysis for CR attainment, OS, and EFS in AML patients with wild-type NPM1 (younger and older patients combined)
| . | CR . | |
|---|---|---|
| Variable . | P* . | Odds ratio (95% CI) . |
| PTPN11, mutated vs wild-type | <.001 | 0.30 (0.16-0.56) |
| TP53, mutated vs wild-type | <.001 | 0.37 (0.24-0.56) |
| FLT3-ITD, positive vs negative | <.001 | 0.44 (0.30-0.63) |
| Age, continuous | <.001 | 0.70 (0.64-0.76) |
| . | CR . | |
|---|---|---|
| Variable . | P* . | Odds ratio (95% CI) . |
| PTPN11, mutated vs wild-type | <.001 | 0.30 (0.16-0.56) |
| TP53, mutated vs wild-type | <.001 | 0.37 (0.24-0.56) |
| FLT3-ITD, positive vs negative | <.001 | 0.44 (0.30-0.63) |
| Age, continuous | <.001 | 0.70 (0.64-0.76) |
| . | OS . | |
|---|---|---|
| Variable . | P* . | Hazard ratio(95% CI) . |
| PTPN11, mutated vs wild-type | .86 | 1.03 (0.73-1.45) |
| WBC count, continuous | .001 | 1.12 (1.05-1.20) |
| Age, continuous | <.001 | 1.38 (1.32-1.44) |
| FLT3-ITD, positive vs negative | .002 | 1.35 (1.12-1.63) |
| TET2, mutated vs wild-type | .002 | 1.38 (1.13-1.70) |
| TP53, mutated vs wild-type | <.001 | 2.74 (2.23-3.37) |
| inv(3)(q21q26)/t(3;3)(q21;q26), yes vs no | <.001 | 2.67 (1.75-4.09) |
| . | OS . | |
|---|---|---|
| Variable . | P* . | Hazard ratio(95% CI) . |
| PTPN11, mutated vs wild-type | .86 | 1.03 (0.73-1.45) |
| WBC count, continuous | .001 | 1.12 (1.05-1.20) |
| Age, continuous | <.001 | 1.38 (1.32-1.44) |
| FLT3-ITD, positive vs negative | .002 | 1.35 (1.12-1.63) |
| TET2, mutated vs wild-type | .002 | 1.38 (1.13-1.70) |
| TP53, mutated vs wild-type | <.001 | 2.74 (2.23-3.37) |
| inv(3)(q21q26)/t(3;3)(q21;q26), yes vs no | <.001 | 2.67 (1.75-4.09) |
| . | EFS . | |
|---|---|---|
| Varibale . | P* . | Hazard ratio(95% CI) . |
| PTPN11, mutated vs wild-type | .14 | 1.27 (0.92-1.75) |
| WBC count, continuous | .004 | 1.10 (1.03-1.18) |
| Age, continuous | <.001 | 1.26 (1.20-1.31) |
| DNMT3A, mutated vs wild-type | .02 | 1.27 (1.04-1.54) |
| FLT3-ITD, positive vs negative | <.001 | 1.54 (1.28-1.85) |
| TET2, mutated vs wild-type | .03 | 1.25 (1.03-1.54) |
| TP53, mutated vs wild-type | <.001 | 2.15 (1.75-2.63) |
| inv(3)(q21q26)/t(3;3)(q21;q26), yes vs no | <.001 | 2.82 (2.5-5.81) |
| . | EFS . | |
|---|---|---|
| Varibale . | P* . | Hazard ratio(95% CI) . |
| PTPN11, mutated vs wild-type | .14 | 1.27 (0.92-1.75) |
| WBC count, continuous | .004 | 1.10 (1.03-1.18) |
| Age, continuous | <.001 | 1.26 (1.20-1.31) |
| DNMT3A, mutated vs wild-type | .02 | 1.27 (1.04-1.54) |
| FLT3-ITD, positive vs negative | <.001 | 1.54 (1.28-1.85) |
| TET2, mutated vs wild-type | .03 | 1.25 (1.03-1.54) |
| TP53, mutated vs wild-type | <.001 | 2.15 (1.75-2.63) |
| inv(3)(q21q26)/t(3;3)(q21;q26), yes vs no | <.001 | 2.82 (2.5-5.81) |
CI, confidence interval; WBC, white blood cell.
P values for logistic and proportional hazard regression are from the likelihood ratio test. An odds ratio <1 (>1) means higher (lower) CR rate for higher values of continuous variables and the first level listed of a dichotomous variable. A hazard ratio >1 (<1) corresponds to a higher (lower) risk for higher values of continuous variables and the first level listed of a dichotomous variable.